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OBJECTIVES We sought to investigate the vascular mechanisms of dobutamine-induced myocardial
ischemia.
BACKGROUND Dobutamine stress is often used as a surrogate for exercise. The effects of dobutamine on the
epicardial arteries are incompletely understood and possibly different from those of physical
exercise.
METHODS Intravenous (IV) dobutamine (40 g/kg per min) was administered in 19 patients with
normal, 23 patients with mildly atherosclerotic, and 12 patients with stenotic coronary
arteries. In another two groups of patients with stenotic arteries, IV dobutamine was preceded
by 1) an intracoronary (IC) bolus of the alpha-adrenergic blocker phentolamine (12 g/kg,
n  12); and 2) an IC infusion of the nitric oxide substrate L-arginine (150 mol/l per min
for 20 min, n 11). Intravenous saline instead of dobutamine was infused into eight patients
with normal arteries. After dobutamine (or saline), an IC bolus of isosorbide dinitrate (ISDN,
0.2 mg) was given. Coronary vasomotion was evaluated by quantitative coronary angiography
on angiograms obtained after each dose of dobutamine, saline, phentolamine, L-arginine, and
ISDN.
RESULTS Dobutamine increased the rate–pressure product and heart rate similarly in all patients except
those who received saline. Dobutamine induced vasodilation in normal (change in luminal
diameter [LD] vs. baseline: 19  2%) and in mildly atherosclerotic arteries (LD: 8  2%,
p  0.05 vs. normal). In stenotic arteries, dobutamine did not induce significant vasomotion
(LD: 3  3%); the latter was improved by L-arginine (LD: 10  3%, p  0.05 vs.
stenotic arteries) and fully restored by phentolamine (LD: 19  3%, p  0.05 vs. stenotic
arteries).
CONCLUSIONS Endothelial dysfunction and enhanced alpha-adrenergic tone contribute to the loss of
dobutamine-induced vasodilation in coronary atherosclerosis. In contrast to physical exercise,
dobutamine does not induce “paradoxical vasoconstriction” of atherosclerotic coronary
arteries. (J Am Coll Cardiol 2003;42:1596–601) © 2003 by the American College of
Cardiology Foundation
Dobutamine stress echocardiography (DSE) is an accepted
surrogate for exercise stress testing to detect significant
coronary atherosclerotic disease (1,2). Several studies have
shown that high-dose intravenous (IV) dobutamine can
induce a mechanical dysfunction when an increase in oxygen
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demand induced by myocardial beta-adrenergic receptor
stimulation is not matched by an adequate increase in
coronary blood flow. In addition, IV dobutamine was shown
to decrease the microvascular resistance to the same extent
as intracoronary adenosine (3,4).
Nevertheless, DSE is clouded by a large number of
false-negative results as compared with hemodynamic as-
sessment of coronary stenosis (5). This may be partly due to
the inability to detect regional wall motion abnormalities
that occur in small territories. Alternatively, this might be
due to a direct vasodilatory effect of dobutamine on athero-
sclerotic epicardial coronary arteries, an effect not observed
during physical exercise. The latter induces “paradoxical”
vasoconstriction of atherosclerotic arteries due to endothe-
lial dysfunction and enhanced alpha-adrenergic receptor
responsiveness (6–11). Dobutamine-induced vasomotion is
thus the net result between dilatory forces (the endothelial
component, through a flow-mediated metabolic response,
and the direct stimulation of vascular and cardiac beta1- and
beta2-adrenergic receptors [12–14]) and constrictive forces
(the direct stimulation of alpha1-adrenergic receptors of the
vascular wall [13]).
Accordingly, in the present study, we investigated the
vasomotion of epicardial arteries during dobutamine infu-
sion in patients with normal, mildly atherosclerotic, and
stenotic coronary arteries. In the latter setting, we further
tested the hypothesis that paradoxical vasoconstriction to
dobutamine does not occur.
METHODS
Patients and protocol. The study population consisted of
85 patients (24 women) with a normal left ventricular
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ejection fraction referred for coronary angiography or per-
cutaneous coronary intervention. In all patients, cardiac
medications, except for aspirin and statins, were withheld
for more than 36 h before the protocol, and no significant
differences in the therapeutic regimen (e.g., angiotensin-
converting enzyme [ACE] inhibitors, statins) were observed
between groups of patients with stenotic coronary arteries
(groups 4, 5, and 6). Patients with valvular heart disease,
unstable angina, a recent myocardial infarction, conduction
system disease, or clinical evidence of heart failure were
excluded.
The patients were classified into six groups according to
the angiographic data and pharmacologic protocol: group 1
consisted of 19 patients (83 coronary segments analyzed)
with angiographically smooth coronary arteries (reference
diameter [RD]: 2.2  0.1 mm). In these patients, angio-
graphic and hemodynamic data were recorded at baseline,
during infusion of dobutamine (increasing dosages of 10,
20, 30, and 40 g/kg per min for 3 min each step), as well
as 1 min after IC isosorbide dinitrate (ISDN; 0.2 mg) given
10 min after cessation of the infusion of dobutamine, when
the heart rate and blood pressure had returned to baseline.
Group 2 consisted of eight patients (34 coronary segments
analyzed) with smooth coronary arteries (RD: 2.2  0.1
mm; pNS vs. group 1). The protocol was identical to that
of group 1, except that dobutamine was replaced by saline.
This was done to rule out the potential influence of the
contrast medium itself on epicardial vasomotion. Group 3
consisted of 23 patients (83 coronary segments analyzed)
with diffuse, mildly atherosclerotic coronaries (30% diam-
eter stenosis; RD: 2.0  0.1 mm). The pharmacologic
protocol and regimen were identical to that of group 1.
Group 4 consisted of 12 patients (36 coronary segments
analyzed) with angiographically documented stenosis in at
least one coronary artery (percent diameter stenosis [%DS]:
49  4%). The coronary segments studied in this group all
belonged to the stenotic artery. The pharmacologic protocol
was identical to that of groups 1 and 3. Group 5 consisted
of 12 patients (55 coronary segments analyzed) who fulfilled
the same angiographic criteria as patients of group 4 (%DS:
47  4; p  NS vs. group 4), but, 3 min before the start of
dobutamine infusion, an IC bolus of phentolamine (12
g/kg), a nonselective alpha-adrenergic blocking agent, was
given (9). Group 6 consisted of 11 patients (63 coronary
segments analyzed) with the same angiographic criteria as
groups 4 and 5 (%DS: 47  4; p  NS vs. groups 4 and 5),
but, 8 min before IV dobutamine, an IC infusion (1.5
ml/min) of the nitric oxide (NO) precursor L-arginine (150
mol/l per min for 20 min) (10,11) was started and
maintained during dobutamine.
Catheterization protocol. A 6F sheath was introduced
into the femoral artery, and a 6F guiding catheter was
engaged into the coronary ostium. Heparin (5,000 U) was
given to all patients, and in case of a coronary intervention,
the dose was adjusted according to the body weight and
need for glycoprotein IIb/IIIa receptor antagonists. On
average, the duration of the protocol was 30 min, and the
protocol was well tolerated by the patients. Informed
consent was obtained from all patients before the diagnostic
catheterization, in accordance with the protocol approved by
the local ethical committee.
Data acquisition. Figure 1 summarizes the study proto-
cols. An angiogram was acquired at baseline, 3 min after IC
administration of phentolamine in group 5, 8 min after the
start of IC infusion of L-arginine in group 6, during the last
15 s of each dosage of dobutamine (or saline) infusion, and
1 min after IC administration of ISDN. In each patient, an
average of 4.1 segments were selected in one projection on
the baseline angiogram. The coronary segments were con-
sidered as follows: in the left anterior descending coronary
artery, the proximal (from the ostium to first septal branch),
the mid (from the first to second septal branch), and the
distal segment (after the second septal branch); in the left
circumflex coronary artery, the proximal (from the ostium to
first marginal branch), the mid (after the first marginal
branch), and the proximal segment of the first marginal
branch (the first 10 mm of the branch); and in the right
coronary artery, the proximal (from the ostium to first acute
marginal branch), the mid (from the first to second acute
marginal branch), and the distal segment (after the second
acute marginal branch). In dominant right coronary arteries,
the proximal 10 mm of the right posterior descending artery
was also considered. In groups 4, 5, and 6 (stenotic arteries),
besides the stenosis, whenever possible, at least one segment
proximal and one segment distal to the stenosis were
obtained. In case of ostial stenosis, two or more segments
distal to the stenosis were obtained. For each segment, the
luminal diameter (LD) was measured at end diastole by
quantitative coronary angiography using the catheter as a
scaling device (3). In case of stenotic coronary arteries,
changes in LD of the stenosis itself were first analyzed
separately from the changes of the adjacent reference seg-
ments. For groups 4, 5, and 6, the data from the stenotic
and adjacent reference segments were pooled, as a uniform
response to dobutamine was observed.
To ensure proper filling of the coronaries with contrast
medium, even during high-flow situations, an angioplasty
guiding catheter was used in every case. Exactly the same
projection was used at the different stages of the protocol.
Based on the emergence of side branches, exactly the same
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segments were analyzed at the different stages of the
protocol. Angiograms were recorded at 25 frames/s. Heart
rate and blood pressures were digitally recorded (Notocord,
France) during the entire study protocol.
The contrast medium used for all patients was the
nonionic monomer, hypo-osmolar ioversol.
Statistical analysis. Data are expressed as the mean value
 SEM. Statistical comparison was made by analysis of
variance (ANOVA) for repeated measurements to compare,
within each group of patients, the effects of different doses
of the drugs being tested. One-way ANOVA was used to
compare the data between different groups. Post hoc anal-
ysis was performed with the Newman-Keuls test. Statistical
analysis was performed with GraphPad Prism, version 2.0.
P values 0.05 were considered nonsignificant.
RESULTS
Systemic hemodynamics (Fig. 2). Dobutamine induced a
similar dose-dependent increase in the rate–pressure prod-
uct in groups 1, 3, 4, 5, and 6. As expected, the adminis-
tration of saline (instead of dobutamine) in group 2 patients
did not produce any hemodynamic changes. The IC admin-
istration of ISDN after the end of the dobutamine/saline
infusion was associated with a significant decrease of the
rate–pressure product in all but group 2. In group 5,
phentolamine administration produced a transient and non-
significant reduction in blood pressure that was completely
normalized after 3 min, when dobutamine infusion was
started. No significant hemodynamic changes were observed
during IC infusion of L-arginine.
Epicardial coronary vasomotion. The results of the drug
regimen in the different groups are shown in Table 1 and
Figures 3 and 4. In group 1 patients (normal coronary
arteries), a significant dose-dependent increase in LD was
observed during infusion of dobutamine. No further in-
crease in LD was observed after ISDN. In group 2 patients
(normal coronary arteries), saline infusion did not result in
any change in LD, whereas ISDN significantly increased
Figure 1. Study protocols. BL  baseline; DOB  dobutamine; IC  intracoronary; ISDN  isosorbide dinitrate; IV  intravenous; Phento 
phentolamine; QCA  quantitative coronary angiography; REC  recovery period; SAL  saline.
Table 1. Changes in Luminal Diameter in the Different Groups of Patients
Dob 10 Dob 20 Dob 30 Dob 40 ISDN
Group 1 (normal arteries) 3  1* 8  1*† 16  2*† 19  2* 22  2*
Group 2 (normal arteries, but dobutamine replaced by saline) 0  1 2  1 2  1 2  1 16  2*†
Group 3 (mildly atherosclerotic arteries) 1  1 4  2* 7  2* 8  2* 17  2*†
Group 4 (stenotic arteries) 6  2* 1  2 1  3 3  3 18  3*†
Group 5 (stenotic arteries pretreated with phentolamine) 2  2 10  2*† 15  2* 19  3* 20  2*
Group 6 (stenotic arteries pretreated with L-arginine) 1  2 6  2* 5  3* 10  3* 15  3*†
*p  0.05 vs. baseline (BL). †p  0.05 vs. preceding value. Data are presented as the mean value  SEM in percent changes compared with baseline.
DOB 10, 20, 30, and 40  dobutamine at 10, 20, 30, and 40 g/kg per min; ISDN  isosorbide dinitrate.
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LD. In group 3 patients (mildly irregular coronary arteries),
a significant dose-dependent increase in LD was observed
during infusion of dobutamine. Yet, this increase was
significantly blunted as compared with group 1. Neverthe-
less, administration of ISDN resulted in a similar increase in
LD as compared with the two previous groups. The data of
groups 4, 5, and 6 take into account the stenosis and
adjacent reference segments of the stenotic coronary artery.
In group 4 patients (with angiographically significant ste-
nosis), apart from transient, minor vasoconstriction occur-
ring at 10 g/kg per min, no significant vasomotion was
observed. A significant increase in LD after ISDN could be
detected. In group 5 patients (with angiographically signif-
icant stenosis), no changes in LD were observed after IC
administration of phentolamine (change in LD of 1  1%
vs. baseline; p  NS). However, after alpha-blockade, the
infusion of dobutamine induced dose-dependent vaso-
dilation similar to that observed in normal arteries. Finally,
in group 6 patients (with angiographically significant
stenosis), no changes in LD were observed after 8 min of
IC infusion of L-arginine (change in LD of 2  2% vs.
baseline; p  NS). Nevertheless, simultaneous administra-
tion of L-arginine and dobutamine was associated with
improved vasodilation.
DISCUSSION
The present study demonstrates that atherosclerosis is
associated with a progressive loss of dobutamine-induced
coronary vasodilation. However, “paradoxical” vasoconstric-
tion, as reported in patients with atherosclerosis during
various forms of stress, was not observed with dobutamine.
Dobutamine-induced vasodilation in patients with severe
atherosclerosis is partially improved by pretreatment with
L-arginine, an NO precursor, and fully restored by phentol-
amine, an alpha1- and alpha2-receptor blocker.
Effects of dobutamine in normal coronary arteries. Our
data show that high-dose dobutamine induces a dose-
dependent dilation of the normal coronary arteries, similar
to intracoronary nitrates. The vasomotor response to dobut-
amine in group 1 is the consequence of direct and indirect
mechanisms: dobutamine causes vasodilation by direct
stimulation of alpha1-, beta1-, and beta2-adrenergic recep-
tors of the coronary vascular wall (12–14). Coronary beta-
Figure 3. Effect of dobutamine on luminal diameter (LD) changes in
group 1 (normal coronary arteries), group 3 (mildly atherosclerotic coro-
nary arteries), and group 4 (stenotic coronary arteries). *p  0.05 vs. group
1. For an explanation of symbols and abbreviations, see Figure 2.
Figure 4. Effect of dobutamine on luminal diameter (LD) changes in
group 4 (stenotic coronary arteries), group 5 (stenotic coronary arteries,
pretreated with phentolamine), and group 6 (stenotic coronary arteries,
pretreated with L-arginine). *p  0.05 vs. group 4. †p  0.05 vs. group 6.
For an explanation of symbols and abbreviations, see Figure 2.
Figure 2. Effect of dobutamine (DOB) and saline on the rate–pressure
product (RPP). *p  0.05 vs. baseline (BL) for dobutamine 20, 30, and 40
g/kg per min in groups 1, 3, 4, and 6; for dobutamine 30 and 40 g/kg
per min in group 5; and for ISDN in group 1. †p 0.05 vs. preceding value
in groups 1, 3, 4, 5, and 6. White boxes represent group 1 (normal
coronary arteries); white circles  group 2 (normal coronary arteries, but
dobutamine replaced by saline); blue diamonds  group 3 (mildly
atherosclerotic coronary arteries); black triangles  group 4 (stenotic
coronary arteries); white triangles  group 5 (stenotic coronary arteries,
pretreated with phentolamine); blue triangles  group 6 (stenotic coro-
nary arteries, pretreated with L-arginine).
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adrenergic relaxation is partly mediated by NO release
activation both in conductance (15) and resistive vessels
(16). However, Ghaleh et al. (17) reported that the vascular
smooth muscle cell component of beta-receptors is the main
regulator of epicardial coronary vasomotion, and endothe-
lium plays only an indirect role by enhancing the vasodila-
tion via a flow-mediated mechanism. Of note, the distribu-
tion of beta-adrenergic receptors on coronary vascular wall is
heterogeneous, as beta1-adrenergic receptors are crucial in
the regulation of coronary vasomotion in epicardial coronary
arteries, whereas beta2-adrenergic receptors become more
important in the regulation of resistance coronaries (16,17).
In addition, dobutamine, by increasing contractility and
myocardial oxygen consumption (18), leads to a release of
vasodilatory substances such as adenosine, which acts on
epicardial arteries and microvasculature (19). Finally, do-
butamine, by increasing the heart rate, induces flow-
mediated epicardial vasodilation (7).
Interestingly, other stress stimuli, including physical ex-
ercise, cold pressor testing, atrial pacing, and mental stress,
induce vasodilation of normal coronaries, mainly via a
flow-mediated mechanism (6–8).
Epicardial vasomotion in atherosclerosis. In contrast, in
patients with atherosclerosis, the latter stimuli were shown
to induce paradoxical vasoconstriction, presumably due to
unopposed alpha-adrenergic vasoconstriction (20–23). The
exercise-induced dilation of normal arteries is attenuated
already at early stages of atherosclerosis in the presence of
hypercholesterolemia (24) and hypertension (25) and with
smoking (26). In the setting of angiographically docu-
mented coronary atherosclerosis, exercise is typically asso-
ciated with vasoconstriction (8). Likewise, cold pressor
testing and atrial pacing were characterized by a reversal of
vasodilation to vasoconstriction with increasing severity of
coronary atherosclerosis (6,7). Furthermore, mental stress
and smoking have been demonstrated to have a similar
vasoconstrictive response in atherosclerotic coronaries
(22,27).
Our data suggest a progressive abolition of dobutamine-
induced coronary vasodilation as a function of the severity of
atherosclerosis. In contrast to what is observed during
physical exercise, paradoxical vasoconstriction was not ob-
served during high doses of dobutamine, not even in
patients with angiographically significant stenoses. The
small constriction at the lowest dose of dobutamine could be
explained by a local vascular response through the alpha-
adrenergic receptor stimulation, as supported by the fact
that this constriction is turned into a dilation after alpha-
blockade (group 5). It can be speculated that a dynamic
equilibrium between vasoconstrictive forces (alpha-
adrenergic receptors, endothelial dysfunction) and vasodila-
tory forces (beta-adrenergic receptors, both vascular and
cardiac) is responsible for the absence of vasoconstriction
during high-dose dobutamine. The significant additional
vasodilation induced by IC nitrates (group 4, stenotic
arteries) suggests that the absence of vasomotion during
dobutamine is not due to vessel stiffness, and that the
vascular smooth muscle cell component of the coronary wall
is still working, allowing the diseased vessel to be responsive
to constrictive or dilatory stimulation.
Role of the coronary endothelium. Progressive endothe-
lial dysfunction could contribute to the loss of vasodilatory
response to dobutamine. This can be related to the impair-
ment of both the endothelial beta-adrenergic receptor com-
ponent and the flow-mediated component of dobutamine-
induced vasodilation. In fact, pretreatment with the NO
precursor L-arginine of the stenotic coronary arteries im-
proved coronary vasodilation to dobutamine, yet did not
fully restore it.
Effects of alpha-receptor blockers. Several studies have
suggested that paradoxical epicardial vasoconstriction in the
presence of atherosclerosis is mediated by an unmasked
alpha-adrenergic vasoconstriction (22,28,29). In patients
with normal coronaries, no significant resting alpha-
adrenergic tone has been found (13). Mildly atherosclerotic
coronary arteries exhibit a more pronounced vasoconstric-
tion to the selective alpha1-agonist phenylephrine. The
latter is paralleled by a vasoconstriction to acetylcholine,
suggesting that endothelial dysfunction is responsible for
the alpha-adrenergic hyper-responsiveness (23). Accord-
ingly, vasoconstriction in response to the cold pressor test
(28), exercise (29), or smoking (22) was abolished by
nonselective alpha- or selective alpha1-blockers in patients
with coronary artery disease.
Our data demonstrate that the blunted vasodilatory
response to dobutamine is also the consequence of enhanced
alpha-adrenergic receptor tone. In patients with docu-
mented coronary stenosis, alpha-blockade, at dosages that
evoke mainly a local effect (9), restored vasomotion in
severely diseased coronary segments.
Clinical implications. Several studies have suggested that
the sensitivity of exercise echocardiography was superior to
that of DSE (30,31). This might be related to a higher level
of oxygen consumption reached by physical exercise. In
addition, as suggested by the present data, it might be
related to the exercise-induced vasoconstriction that is not
observed during dobutamine. Finally, the concomitant
treatment with alpha-blockers of patients undergoing DSE
could further contribute to false-negative results.
Study limitations. Some of the variables that might influ-
ence the inter- and intra-individual vascular response to
dobutamine have not been addressed in the present study.
Concomitant medical therapy, even though mostly with-
drawn 36 h before, might have influenced the vasomotor
response to dobutamine. In particular, drugs like ACE
inhibitors and statins, which improved the endothelial
function, could enhance the vasodilation to dobutamine.
However, in the groups of patients with stenotic coronary
arteries (groups 4, 5, and 6), no significant differences were
observed concerning concomitant drug categories.
Diurnal variations of the endothelial vasomotor response
have been reported (32,33). In particular, coronary seg-
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ments with dysfunctional endothelium showed a hyper-
responsiveness in the early morning (32). Most of the
patients recruited have been studied in the morning (be-
tween 8:00 and 11:00 AM). No difference was present
between the several groups concerning the number of
patients not studied during this time window.
Coronary angiograms have been obtained by contrast
hand injection. This approach bears the following limita-
tions: 1) the injected contrast volume is not constant; 2) the
injection does not always start in the same part of the
cardiac cycle; and 3) filling of the coronaries depends on the
operator and vessel size. To minimize these sources of
variability, 6F guiding catheters (instead of a diagnostic
catheter) have been used in all patients, and long contrast
injections (over three cardiac beats) have been performed.
Conclusions. Dobutamine induces a dose-dependent va-
sodilation in normal and mildly atherosclerotic coronaries,
although a lack of vasomotion is observed in stenotic
coronaries. The latter is related to the endothelial dysfunc-
tion and enhanced alpha-adrenergic responsiveness. The
absence of paradoxical coronary vasoconstriction during
dobutamine infusion may be partly responsible for the
false-negative results of DSE.
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